Dental/Medical Diagnostic Systems Announces Late Fall Launch of the Apollo e.Light High-Speed Curing Device.

Business Editors

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Oct. 17, 2000

New L.E.D. Curing Technology Offers Wireless Portability

and Cures in as Little as 6 Seconds

Dental/Medical Diagnostic Systems Inc. (Nasdaq:DMDS) today announced it will begin shipping its new curing device, Apollo(TM) e.Light, in November 2000.

The prior announced launch date of late September 2000 was delayed as the Company did not receive parts that met set specification requirements. The new Apollo(TM) e.Light offers significant technological advancements over the Company's successful Apollo(TM) product series.

The Apollo(TM) e.Light contains an array of Light Emitting Diodes (LEDs) that provides a fast and effective solution for curing composite fillings in teeth. Additionally, the new Apollo(TM) e.Light cures composite materials faster than most curing lights available in the dental marketplace by providing six-second curing (per layer) versus the 40 seconds (per layer) that is typical for curing a filling using existing systems.

Spending as little chair-time as possible is important to dentists, as the more patients they can serve, the greater their efficiency and revenue productivity. The cordless device also offers dentists freedom that has not been available in the past, since the absence of any attachment to the base unit simplifies access to the patients' mouths. This ergonomic feature is a significant convenience for a dentist or technician in the small, often crowded dental operatory.

The new Apollo(TM) e.Light is priced at $2,495, a substantially lower cost

than competitive fast-curing lights. Conventional (slow) curing devices generally cost between $800 and $1,500.

Additional advantages of the Apollo(TM) e.Light are that it produces no heat that could potentially injure the patient's soft tissues or teeth, is custom-programmable by bar code or the Internet for any specific composite used and does not require maintenance, unlike fast curing light bulbs, which may need to be replaced frequently at a high cost, where the LED array has an almost unlimited life.

The Apollo(TM) e.Light will be offered to major universities and teaching institutions as the most effective strategy for rapidly capturing the awareness of dentists and building market share. DMDS management foresees the Apollo(TM) e.Light making significant inroads into a market valued internationally at approximately $300 million per year.

"We are very excited about the launch of the Apollo(TM) e.Light," said Robert Gurevitch, Chairman and CEO of Dental/Medical Diagnostic Systems Inc. "We are extremely optimistic about the product's reception once it hits the marketplace. The Apollo 95E was a very successful product that generated revenues of approximately $40 million. Given that the Apollo(TM) e.Light is patented, sells at a substantially lower price and cures in just a few seconds, we are looking forward to the impact it will have on our sales and earnings."

Dental/Medical Diagnostic Systems Inc. (www.dmdcorp.com) develops and markets proprietary products for dentistry, targeting broad market segments and seeking dominance through superior technological innovations. Its current lead products are the Apollo(TM) line of devices used for "curing" (hardening) fillings and/or whitening teeth in the dentist's office and a state-of-the-art dental digital x-ray system.

This news release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 ("Securities Act") and Section 21E of the Securities Exchange Act of 1934 (The "Exchange Act"). Although the Company believes that the expectations reflected in such forward-looking statements are reasonable at this time, it can give no assurance that such expectations will prove to have been correct. Forward-looking statements involve numerous risks and uncertainties described in the Company's most recently filed Current Report on Form 8-K, Quarterly Report on Form 10-Q and Annual Report on Form 10-K filed with the Securities and Exchange Commission which should be read in conjunction herewith, copies of which are available from the Company's investor relations department. Actual results may differ materially from those contemplated by the forward-looking statements set forth herein. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any statement herein or to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.